Allergy Antihistamine

Diphenhydramine Hydrochloride


Best Choice (valu Merchandisers Company)
Human Otc Drug
NDC 63941-690
Allergy Antihistamine also known as Diphenhydramine Hydrochloride is a human otc drug labeled by 'Best Choice (valu Merchandisers Company)'. National Drug Code (NDC) number for Allergy Antihistamine is 63941-690. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Allergy Antihistamine drug includes Diphenhydramine Hydrochloride - 25 mg/1 . The currest status of Allergy Antihistamine drug is Active.

Drug Information:

Drug NDC: 63941-690
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Allergy Antihistamine
Also known as the trade name. It is the name of the product chosen by the labeler.
Proprietary Name Base: Allergy
The base of the Brand/Proprietary name excluding its suffix.
Proprietary Name Suffix: Antihistamine
A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Diphenhydramine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Best Choice (valu Merchandisers Company)
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIPHENHYDRAMINE HYDROCHLORIDE - 25 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Aug, 2010
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 Dec, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part341
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 16 Jan, 2025
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Best Choice (Valu Merchandisers Company)
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1049630
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0070038582519
UPC stands for Universal Product Code.
UNII:TC2D6JAD40
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63941-690-011 BOTTLE in 1 BOX (63941-690-01) / 100 TABLET in 1 BOTTLE27 Aug, 201031 Dec, 2023No
63941-690-242 BLISTER PACK in 1 CARTON (63941-690-24) / 12 TABLET in 1 BLISTER PACK27 Aug, 201031 Dec, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose antihistamine

Product Elements:

Allergy antihistamine diphenhydramine hydrochloride diphenhydramine hydrochloride diphenhydramine carnauba wax silicon dioxide croscarmellose sodium d&c red no. 27 calcium phosphate, dibasic, dihydrate hypromelloses magnesium stearate cellulose, microcrystalline polyethylene glycol 400 polysorbate 80 polyvinyl alcohol, unspecified talc titanium dioxide aluminum oxide egg phospholipids water t61;v25;s4

Indications and Usage:

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat temporarily relieves these symptoms due to common cold: runny nose sneezing

Warnings:

Warnings do not use to make a child sleepy with any other product containing diphenhydramine, even one used on skin ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. when using this product marked drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery excitability may occur, especially in children if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. (1-800-222-1222)

Do Not Use:

Warnings do not use to make a child sleepy with any other product containing diphenhydramine, even one used on skin ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. when using this product marked drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery excitability may occur, especially in children if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. (1-800-222-1222)

When Using:

When using this product marked drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery excitability may occur, especially in children

Dosage and Administration:

Directions take every 4 to 6 hours or as directed by a doctor do not take more than 6 doses in 24 hours adults and children 12 years and over take 1 to 2 tablets children 6 to under 12 years take 1 tablet children under 6 years do not use this product in children under 6

Package Label Principal Display Panel:

Principal display panel compare to the active ingredient of benadryl® allergy** antihistamine allergy relief diphenhydramine hcl 25 mg for allergy relief sneezing, itchy, watery eyes, runny nose, itchy throat tablets **this product is not manufactured or distributed by mcneil consumer healthcare,distributor of benadryl ® allergy tamper evident: do not use if carton is opened or if blister unit is torn, broken or show any sign of tampering keep outer carton for complete warnings and product information. proudly distributed by: valu merchandisers, co. 5000 kansas ave kansas city, ks 66106 www.bestchoicebrand.com

Product label best choice allergy relief tablets diphenhydramine hci 25 mg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.